Estimates your kidney filtration rate using the 2021 CKD-EPI equation (race-free). Shows your CKD stage, kidney function category, and how your eGFR connects to your cardiovascular risk in the PREVENT calculator.
Inker LA et al., NEJM 2021 · Race-free · KDIGO 2024 recommended
| Stage | eGFR (mL/min/1.73m²) | Description |
|---|
| DOAC | Dose reduction | Contraindicated |
|---|---|---|
| Apixaban | Per criteria (age/weight/creatinine) | eGFR < 15 |
| Rivaroxaban (AFib) | eGFR < 50 → 15mg daily | eGFR < 15 |
| Dabigatran | eGFR 30–50 (consider dose reduction) | eGFR < 30 |
| Edoxaban | eGFR < 50 → 30mg daily | eGFR < 15 |
Thresholds shown are for AFib indication. Confirm current prescribing information with your pharmacist.
This calculator uses the 2021 CKD-EPI creatinine equation (Inker LA et al., N Engl J Med 2021;385:1737–49). It's the race-free update to the original 2009 CKD-EPI equation, recommended by the NKF-ASN Task Force and now endorsed by KDIGO 2024 guidelines.
The 2021 equation takes 3 inputs: serum creatinine, age, and sex. That's it. No race variable.
The original 2009 equation included a race coefficient that delayed CKD diagnosis in Black patients. The 2021 update removed it. Most US labs switched to the 2021 equation by 2023.
eGFR is a direct input in the AHA 2023 PREVENT cardiovascular risk equations. Your kidney function affects your 10-year CVD risk estimate, and PREVENT is the only major risk tool that captures this.
All 4 oral anticoagulants require dose adjustments or are contraindicated at certain eGFR thresholds. This page shows those cutoffs so you can have a more informed conversation with your prescriber.
An eGFR of 60 or above is generally considered adequate kidney function for most adults. Below 60 for more than 3 months — or above 60 with signs of kidney damage like significant albuminuria — meets the KDIGO definition of chronic kidney disease.
A few things worth knowing about eGFR interpretation:
The 2009 CKD-EPI equation included a race coefficient that produced higher eGFR estimates for Black patients, based on population-level data about muscle mass. The NKF-ASN Task Force found this had real clinical consequences: Black patients received higher eGFR estimates, which delayed their qualification for nephrology referrals, transplant waitlisting, and treatment.
The 2021 equation removed race entirely. For Black patients, this typically produces eGFR estimates 16% lower than the 2009 equation — meaning earlier identification of CKD and earlier access to treatment.
Kidney disease and heart disease share the same risk factors and accelerate each other. The medical term for this overlap is cardiovascular-kidney-metabolic (CKM) syndrome.
The 2023 AHA PREVENT equations are the first major cardiovascular risk tool to include eGFR as a direct input. An eGFR below 60 meaningfully increases your PREVENT risk estimate. Below 45, the effect on CVD risk is substantial. Calculate your PREVENT cardiovascular risk here.
If you're on a DOAC for atrial fibrillation or another indication, your eGFR directly determines whether dose adjustment is needed. All 4 approved DOACs are partially renally cleared, and standard doses can accumulate to dangerous levels in patients with reduced kidney function.
Your pharmacist recalculates this at every prescription fill. But knowing your own eGFR helps you ask the right questions. If you have AFib, check your CHA₂DS₂-VASc score alongside your eGFR — your prescriber needs both.
An eGFR of 90 or above (G1) with no other kidney damage markers is normal. G2 (60–89) is mildly reduced but not CKD on its own. Below 60 for more than 3 months is CKD by KDIGO definition. Below 15 (G5) is kidney failure.
Most US labs transitioned between 2022 and 2023 following the NKF-ASN Task Force recommendation. The 2021 equation removes the race variable. If your eGFR appears slightly lower than previous results, that's likely why — the new equation doesn't apply the race-based upward adjustment the old one did.
The 2021 CKD-EPI formula uses serum creatinine, age, and sex. The full equation uses different exponents depending on whether your creatinine is above or below the sex-specific threshold (0.7 for women, 0.9 for men). This calculator applies the correct equation branch automatically.
An eGFR below 30 (G4) warrants nephrology referral in most guidelines. Below 15 (G5) typically requires preparation for renal replacement therapy (dialysis or transplant). From a DOAC safety perspective, dabigatran is contraindicated below eGFR 30 and rivaroxaban/edoxaban require dose reduction below eGFR 50.
Yes, particularly when the underlying cause is treatable. Optimizing blood pressure, controlling diabetes, stopping nephrotoxic medications, and treating obstructive causes can all stabilize or improve eGFR. ACE inhibitors and ARBs are kidney-protective in diabetic nephropathy. SGLT2 inhibitors have shown meaningful kidney protection in trials published between 2019 and 2023.